ArticleDrug delivery2018
Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.
Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 116 citations in OpenAlex.
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
- Targeted Delivery of Triptolide Via Folate-Functionalized Pluronic Micelles Enhances Anti-Melanoma Activity by Inducing Reactive Oxygen Species Accumulation.BioMed research international · 2026Article
- Active Targeting Strategies for Improving the Bioavailability of Curcumin: A Systematic Review.Foods (Basel, Switzerland) · 2025Review
- Strategic advances in liposomes technology: translational paradigm in transdermal delivery for skin dermatosis.Journal of nanobiotechnology · 2025Review
- Article
- Targeted mitochondrial therapy for pancreatic cancer.Translational oncology · 2025Review
- Effect of Biomedical Hydrogels on Exercise-induced Muscle Damage: A Narrative Review.Current medicinal chemistry · 2025Review
- Review
- Pulmonary inhalation for disease treatment: Basic research and clinical translations.Materials today. Bio · 2024Review
- A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors.Bioengineering & translational medicine · 2024Review
- Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer.Molecules (Basel, Switzerland) · 2024Review
- Targeted Molecular Therapeutics for Pulmonary Diseases: Addressing the Need for Precise Drug Delivery.Handbook of experimental pharmacology · 2024Article
- Liposomal Nano-Based Drug Delivery Systems for Breast Cancer Therapy: Recent Advances and Progresses.Anti-cancer agents in medicinal chemistry · 2024Review
- Inhaled Medicines for Targeting Non-Small Cell Lung Cancer.Pharmaceutics · 2023Review
- Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC).Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Recent Advances in Lung Cancer Therapy Based on Nanomaterials: A Review.Current medicinal chemistry · 2023Review
- Hydroxyethylcellulose-Based Hydrogels Containing Liposomes Functionalized with Cell-Penetrating Peptides for Nasal Delivery of Insulin in the Treatment of Diabetes.Pharmaceutics · 2022Article
- Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy.Acta pharmacologica Sinica · 2022Review
- Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics.Biomedicines · 2022Review
- γ-Cyclodextrin metal-organic framework as a carrier to deliver triptolide for the treatment of hepatocellular carcinoma.Drug delivery and translational research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The abilities of a drug delivery system to target and penetrate tumor masses are key factors in determining the system's chemotherapeutic efficacy. Here, we explored the utility of an anti-carbonic anhydrase IX (anti-CA IX) antibody and CPP33 dual-ligand modified triptolide-loaded liposomes (dl-TPL-lip) to simultaneously enhance the tumor-specific targeting and increase tumor cell penetration of TPL. In vitro, the dl-TPL-lip increased the cytotoxicity of TPL in CA IX-positive lung cancer cells, which showed tunable size (137.6 ± 0.8 nm), high-encapsulation efficiency (86.3 ± 2.6%) and sustained release. Dl-TPL-lip significantly improved the ability of liposomes to penetrate 3 D tumor spheroids and exhibited a superior inhibiting effect. Furthermore, pharmacokinetic studies in rats that received TPL liposomal formulations by endotracheal administration showed a reduced concentration of TPL (17.3%-30.6% compared to free TPL) in systemic circulation. After pulmonary administration in orthotopic lung tumor-bearing mice, dl-TPL-lip significantly enhanced TPL anti-cancer efficacy without apparent systemic toxicity. This dual-ligand modified liposomal vehicle presents a potential system for localized and targeted delivery of anti-cancer drugs to improve their efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.